Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach

International Journal of Oncology

Volumn 48, Issue 6, 2016, Pages 2591-2607

  Li, Qingdi Quentin ^a   Hao, Jian Jiang ^b   Zhang, Zheng ^b   Hsu, Iawen ^a   Liu, Yi ^b   Tao, Zhen ^b   Lewi, Keidren ^a   Metwalli, Adam R ^a   Agarwal, Piyush K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Poochon Scientific   (United States)

Author keywords

Apoptosis; Bladder cancer; Cell cycle; DNA damage repair; HDAC inhibitor; Pathway analysis; Proteomics

Indexed keywords

FREE RADICAL; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEOME; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; TRICHOSTATIN A; VORINOSTAT; ANTINEOPLASTIC AGENT; DEPSIPEPTIDE; HYDROXAMIC ACID;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BIOINFORMATICS; BLADDER CANCER; BLADDER CANCER CELL LINE; CELL CYCLE PROGRESSION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; HISTONE ACETYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; UPREGULATION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEPSIPEPTIDES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84964595295     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3478     Document Type: Article

References (56)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66: 7-30, 2016.
2. Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet 374: 239-249, 2009.
3. Weintraub MD, Li QQ and Agarwal PK: Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (review). Mol Clin Oncol 2: 656-660, 2014.
4. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A and Witjes JA; European Association of Urology (EAU): Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. Eur Urol 59: 1009-1018, 2011.
5. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: Causes and therapies. Nat rev Cancer 1: 194-202, 2001.
6. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
7. Marks PA and Xu WS: Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600-608, 2009.
8. Schrump DS: Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer res 15: 3947-3957, 2009.
9. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, et al: expression profile of class I histone deacetylases in human cancer tissues. Oncol rep 18: 769-774, 2007.
10. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S and Iwase H: Quantitation of HDAC1 mrNA expression in invasive carcinoma of the breast. Breast Cancer res Treat 94: 11-16, 2005.
11. Marquard L, Poulsen CB, Gjerdrum LM, De Nully Brown P, Christensen IJ, Jensen PB, Sehested M, Johansen P and Ralfkiaer E: Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 54: 688-698, 2009.
12. Witt O, Deubzer HE, Milde T and Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8-21, 2009.
13. Ozawa A, Tanji N, Kikugawa T, Sasaki T, Yanagihara Y, Miura N and Yokoyama M: Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int 105: 1181-1186, 2010.
14. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat rev Drug Discov 5: 769-784, 2006.
15. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat rev Cancer 6: 38-51, 2006.
16. Yoshida M, Kijima M, Akita M and Beppu T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179, 1990.
17. Tan J, Cang S, Ma Y, Petrillo RL and Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: 5, 2010.
18. Mcgraw AL: romidepsin for the treatment of T-cell lymphomas. Am J Health Syst Pharm 70: 1115-1122, 2013.
19. Li QQ, Wang G, Liang H, Li JM, Huang F, Agarwal PK, Zhong Y and Reed E: β-elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas. Anticancer res 33: 1421-1428, 2013.
20. Florens L, Carozza MJ, Swanson SK, Fournier M, Coleman MK, Workman JL and Washburn MP: Analyzing chromatin remodeling complexes using shotgun proteomics and normalized spectral abundance factors. Methods 40: 303-311, 2006.
21. Paoletti AC, Parmely TJ, Tomomori-Sato C, Sato S, Zhu D, Conaway RC, Conaway JW, Florens L and Washburn MP: Quantitative proteomic analysis of distinct mammalian mediator complexes using normalized spectral abundance factors. Proc Natl Acad Sci USA 103: 18928-18933, 2006.
22. Ou JN, Torrisani J, Unterberger A, Provençal N, Shikimi K, Karimi M, Ekström TJ and Szyf M: Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 73: 1297-1307, 2007.
23. Swanton C: Cell-cycle targeted therapies. Lancet Oncol 5: 27-36, 2004.
24. Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1995.
25. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
26. Dynlacht BD: regulation of transcription by proteins that control the cell cycle. Nature 389: 149-152, 1997.
27. Wesierska-gadek J, Gueorguieva M and Horky M: Dual action of cyclin-dependent kinase inhibitors: Induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharmacol 55: 895-902, 2003.
28. Parker LL, Sylvestre PJ, Byrnes MJ III, Liu F and Piwnica-Worms H: Identification of a 95-kDa Wee1-like tyrosine kinase in HeLa cells. Proc Natl Acad Sci USA 92: 9638-9642, 1995.
29. Mitra J and Enders GH: Cyclin A/Cdk2 complexes regulate activation of Cdk1 and Cdc25 phosphatases in human cells. Oncogene 23: 3361-3367, 2004.
30. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78: 539-542, 1994.
31. Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer res 56: 1253-1255, 1996.
32. Blagosklonny MV, Schulte T, Nguyen P, Trepel J and Neckers LM: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer res 56: 1851-1854, 1996.
33. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L and Fojo T: raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer res 57: 130-135, 1997.
34. Haldar S, Basu A and Croce CM: Bcl2 is the guardian of micro-tubule integrity. Cancer res 57: 229-233, 1997.
35. Haldar S, Basu A and Croce CM: Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer res 58: 1609-1615, 1998.
36. Chang BS, Minn AJ, Muchmore SW, Fesik SW and Thompson CB: Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J 16: 968-977, 1997.
37. Roos WP, Thomas AD and Kaina B: DNA damage and the balance between survival and death in cancer biology. Nat rev Cancer 16: 20-33, 2016.
38. Friedberg EC, Walker GC, Siede W and Schultz RA: DNA Repair and mutagenesis. 2nd edition. ASm Press, Washington, DC, 2006.
39. Halliwell B: Free radicals, antioxidants, and human disease: Curiosity, cause, or consequence? Lancet 344: 721-724, 1994.
40. Brot N, Weissbach L, Werth J and Weissbach H: enzymatic reduction of protein-bound methionine sulfoxide. Proc Natl Acad Sci USA 78: 2155-2158, 1981.
41. Demple B and Linn S: 5, 6-Saturated thymine lesions in DNA: Production by ultraviolet light or hydrogen peroxide. Nucleic Acids res 10: 3781-3789, 1982.
42. Xia T, Kovochich M, Brant J, Hotze M, Sempf J, Oberley T, Sioutas C, Yeh JI, Wiesner MR and Nel AE: Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett 6: 1794-1807, 2006.
43. Feng R, Oton A, Mapara MY, Anderson G, Belani C and Lentzsch S: The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 139: 385-397, 2007.
44. Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, Dent P and Grant S: The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 69: 216-225, 2006.
45. Feng R, Ma H, Hassig CA, Payne JE, Smith ND, Mapara MY, Hager JH and Lentzsch S: KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol Cancer Ther 7: 1494-1505, 2008.
46. Rosato rr, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P and Grant S: role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther 7: 3285-3297, 2008.
47. Orrenius S, Gogvadze V and Zhivotovsky B: mitochondrial oxidative stress: Implications for cell death. Annu rev Pharmacol Toxicol 47: 143-183, 2007.
48. Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, et al: Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer res 16: 4742-4754, 2010.
49. Rao R, Nalluri S, Kolhe R, Yang Y, Fiskus W, Chen J, Ha K, Buckley KM, Balusu R, Coothankandaswamy V, et al: Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Mol Cancer Ther 9: 942-952, 2010.
50. Kahali S, Sarcar B, Prabhu A, Seto E and Chinnaiyan P: Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. FASeB J 26: 2437-2445, 2012.
51. Yi C, Ma M, Ran L, Zheng J, Tong J, Zhu J, Ma C, Sun Y, Zhang S, Feng W, et al: Function and molecular mechanism of acetylation in autophagy regulation. Science 336: 474-477, 2012.
52. Hassler MR and Egger G: Epigenomics of cancer - emerging new concepts. Biochimie 94: 2219-2230, 2012.
53. Jerónimo C and Henrique R: Epigenetic biomarkers in urological tumors: A systematic review. Cancer Lett 342: 264-274, 2014.
54. Bannister AJ and Kouzarides T: regulation of chromatin by histone modifications. Cell Res 21: 381-395, 2011.
55. Abbosh PH, McConkey DJ and Plimack ER: Targeting signaling transduction pathways in bladder cancer. Curr Oncol rep 17: 58, 2015.
56. O'rourke CJ, Knabben V, Bolton E, Moran D, Lynch T, Hollywood D and Perry AS: manipulating the epigenome for the treatment of urological malignancies. Pharmacol Ther 138: 185-196, 2013.